Testing a medicine injected into tumors for advanced cancers
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 1 study tests IVX037, a medicine given directly into a solid tumor, to see if it is safe and may shrink tumors. It is for people with certain advanced colorectal, stomach/gastroesophageal, or ovarian cancers that have limited treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer, stomach/gastroesophageal adenocarcinoma, or ovarian cancer, and it has progressed or is not suitable for standard whole-body treatments.
- Your colorectal cancer must be mismatch-repair “proficient” (not microsatellite unstable), confirmed by tumor testing.
- You must have had at least one prior treatment using whole-body anticancer medicine, but no more than 3 total treatment “lines” (for some stomach cancers, you must have had and failed an immune checkpoint drug).
- You must have at least one measurable tumor spot that doctors can inject (often a liver lesion or a lymph node), and there are size limits for the tumor areas they can use.
- You must be able to have study treatment safely: good general strength (ECOG 0–1), enough organ function on recent bloodwork, and you should be mostly recovered from prior side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two medicines, pin and sintilimab, for people with advanced colorectal cancer that has spread to the liver and has already been treated with at least two standard therapies. The study aims to see if injecting the medicine directly into the liver tumor, combined with immunotherapy through a vein, can shrink tumors and help patients live longer.
This trial tests a combination of two drugs (liposomal irinotecan and sintilimab) for people with stomach or gastroesophageal junction cancer that has progressed after at least one round of standard chemotherapy. The goal is to see if this combo can help shrink tumors or slow the cancer's growth.
This trial tests a modified virus injected directly into tumors to treat metastatic gastrointestinal and peritoneal cancers. It aims to see if this approach can shrink tumors or slow their growth.
This Phase 1/2 trial tests T3P, a new treatment given directly into reachable solid tumors, to see if it is safe and can help shrink tumors. It is for adults with advanced cancers when no curative treatment is available.
This trial tests an experimental injection called Ixovex-1, either alone or with another drug (pembrolizumab), for people with advanced solid tumors that can be injected. It is for those who have run out of standard options and have tumors that are not too deep inside the body.
This Phase 1 trial studies a new cancer medicine (IBI343) that targets certain tumor cells to see how safe it is and how well it may work. You may be eligible if you have advanced, hard-to-remove cancers and your tumor has a specific marker called CLDN18.2.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.